1Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell ru ",l in patients with sepsis, shock, and multiple organ dysfunction [J] . Crit Care Med, 1999, 27 (7) : 1230-1251.
2Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis4nduced apoptosis causes progressive profound depletion of B and CD4 +T lymphocytes in humans [J]. J Immunol, 2001, 166 (11):6952-6963.
3Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic ceils, but not macrophages, in patients with sepsis [ J ]. J Immunol, 2002, 168 (5) : 2493-2500.
4Le Tulzo Y, Pangauh C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome [J]. Shock, 2002, 18 (6): 487-494.
5Hotchkiss RS, Osmon SB, Chang KC, et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways [J]. J Immunol, 2005, 174 (8): 5110- 5118.
7Hotchkiss RS, Opal S. Immunotherapy for sepsis-a new approach against an ancient foe [J]. N Engl J Med, 2010, 363 ( 1 ) : 87- 89.
8Muenzer JT, Davis CG, Chang K, et al. Characterization and modulation of the immunosuppressive phase of sepsis [ J ]. Infect Immun, 2010, 78 (4) : 1582-1592.
9Meisel C, Schefold JC, Pschowski R, et al. Granulocyte- macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression : a double-blind, randomized, placebo- controlled multicenter trial [ J ]. Am J Respir Crit Care Med, 2009, 180 (7): 640-648.
10Scumpia PO, Delano M J, Kelly-Scumpia KM, et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis [J]. Blood, 2007, 110 (10): 3673-3681.
3Riedemann N C,Guo R F,Ward P A,et al.The enigma of sepsis[J].J Clin Invest,2003,112(4):460-467.
4Vermes I,Haanen C,Steffens-Nakken H,et al.A novel assay for apoptosis:flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V[J].J Immunol Methods,1995,184(1):39-51.
5Hotchkiss R S,Osmon S B,Chang K C,et al.Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways[J].J Immunol,2005,174(8):5110-5118.
6Papathanassoglou E D,Moynihan J A,McDermott M P,et al.Expression of Fas(CD95)and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival[J].Crit Care Med,2001(11),29:709-718.
7Le Tulzo Y,Pangault C,Gacouin A,et al.Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome[J].Shock,2002,18(6):487-494.
8Krautwald S,Ziegler E,Tiede K,et al.Transduction of the TAT-FLIP fusion protein results in transient resistance to Fas-induced apoptosis in vivo[J].J Biol Chem,2004(42),279:44005-44011.
2Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 [J]. Crit Care Med, 2013, 41 (2): 580-637.
3Briegel J, Mohnle p, Dellinger RP, et al. International guidelines of the Surviving Sepsis Campaign : update 2012 [ J ]. Anaesthesist, 2013, 62 ( 4 ) : 304-309.
4Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update [J]. Expert Rev Anti Infect Ther, 2011, 9 (11): 1013-1033.
5Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis Is individualized immuno-modulatory therapy the answer [J]. Virulence, 2014, 5 (1): 45-56.
6Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure [ J ]. JAMA, 2011, 306 (23) : 2594-2605.
7de Pablo R, Monserrat J, Pfieto A, et al. Role of circulating lymphocytes in patients with sepsis [ J]. Biomed Res Int, 2014, 2014: 671087.
8Wiersinga WJ, Leopold SJ, Cranendonk DR, et al. Host innate immune responses to sepsis [J]. Virulence, 2014, 5 (1) : 36- 44. 5436.
9Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy [J]. Nat Rev Immunol, 2013, 13 (12): 862-874.
10Almansa R, Wain J, Tamayo E, et al. Immunological monitoring to prevent and treat sepsis [ J]. Crit Care, 2013, 17 ( 1 ) : 109.
